A Microdose Evaluation Study of ABY-029 in Recurrent Glioma

NCT02901925 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Glioma

Interventions

DRUG: ABY-029

Sponsor

Dartmouth-Hitchcock Medical Center

Collaborators

[object Object]
[object Object]